Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

SSSE:600267
12.85
CNY
+0.02
(+0.16%)
1.07EPS
11.09P/E
13.87BMarket Cap
Mar 26Next Earn
Zhejiang Hisun Pharmaceutical Co., Ltd. Class A
SSE:600267
(Shanghai Stock Exchange)

Recent

price

12.85

P/E

ratio

11.09

div

yld

2.02%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
5.9
6.25
6.93
10.26
11.48
6.46
10.31
7.79
10.55
11.9
11.7
10.22
9.78
8.63
8.94
8.97
7.91
Revenue per Share
0.48
0.61
0.36
0.36
0.35
0.01
-0.1
0.01
-0.51
0.1
0.43
0.43
0.42
-0.08
0.52
0.46
1.06
Basic EPS, GAAP
-0.41
-0.93
-1.5
-1.9
-1.8
-0.88
-1.05
-0.08
-0.16
-0.41
0.93
1
1.39
1.04
1.68
1.41
- -
Free Cash Flow per Basic Share
0.23
0.25
0.33
0.44
0.57
0.23
0.54
0.39
0.56
0.54
0.48
0.37
0.33
0.31
0.13
0.29
0.26
Dividend per Share
3.49
5.36
5.58
5.82
7.27
7.17
7
6.96
6.4
6.5
6.92
6.11
6.74
6.71
6.96
7.18
8.06
Book Value per Share
2.99
4.8
4.93
5.02
6.45
5.88
5.38
5.03
3.9
5.1
5.53
4.77
5.47
5.68
6.13
6.47
7.4
Tangible Book Value per Share
770
826
837
838
880
1,357
944
1,357
966
931
970
1,132
1,164
1,165
1,156
1,175
1,156
Basic Weighted Avg Shares
4,545
5,161
5,802
8,604
10,097
8,767
9,733
10,572
10,187
11,072
11,354
11,572
11,379
10,053
10,340
10,550
9,148
Sales/Revenue/Turnover
10.69
12.43
6.08
8.65
8.39
2.01
3.27
6.04
4.06
0.33
10.17
9.4
10.01
5.24
9.79
12.14
18.11
Operating Margin (%)
260
291
333
346
426
547
606
674
745
885
874
952
1,040
1,048
1,087
979
- -
Depreciation Expense
366
504
301
302
308
14
-94
14
-492
93
417
487
489
-93
601
541
1,225
Net Income, GAAP
16.8
16.7
18.48
23.28
30.87
39.67
67.01
33.31
- -
36.25
20.02
20.69
28.12
- -
17.65
32.85
22.56
Effective Tax Rate (%)
8.05
9.77
5.19
3.51
3.05
0.15
-0.97
0.13
-4.83
0.84
3.67
4.21
4.3
-0.93
5.81
5.13
13.4
Profit Margin (%)
420
1,574
1,310
563
1,474
341
-125
-1,137
-3,429
-2,245
-3,190
-2,421
-724
-225
-477
-423
329
Working Capital
1,506
1,920
2,279
2,378
3,155
3,989
4,944
4,961
4,187
2,925
1,135
2,796
3,089
2,398
1,066
204
54
LT Debt
2,744
4,594
5,198
5,958
8,265
8,165
8,039
7,875
7,379
7,683
8,257
7,346
8,330
8,349
8,579
8,852
9,777
Total Equity
7.74
7.81
2.84
4.16
3.34
0.23
0.02
0.9
- -
1.91
3.74
3.5
3.31
- -
4.42
4.69
10.44
Return on Invested Capital (%)
8.58
8.88
4.84
1.92
1.6
0.3
-0.86
0.01
- -
1.14
2.71
4.69
4.69
- -
5.5
4.86
10.61
Return on Capital (%)
14.38
14.01
6.56
6.31
5.17
0.19
-1.38
0.2
-7.63
1.49
6.44
6.97
6.36
-1.15
7.31
6.38
13.72
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,139
1,717
1,493
LT Borrowings
35
- -
- -
LT Finance Leases
49
57
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,199
1,180
1,180
Market Capitalization
12,551
11,933
13,868

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,373
3,826
4,168
Cash, Cash Equivalents & STI
1,857
1,139
1,177
Accounts Receivable, Net
746
1,041
1,098
Inventories
1,356
1,314
1,449
Total Current Liabilities
4,387
4,098
3,839
Payables & Accruals
- -
- -
- -
ST Debt
2,139
1,717
1,493
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.02%
1.71%
3.18%
Free Cash Flow
-16.81%
17.87%
-14.92%
Net Income, GAAP
-526.84%
-171.45%
-10.06%
Sales/Revenue/Turnover
2.07%
-1.3%
2.03%
Total Cash Common Dividend
10.61%
9.65%
131.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,727
2,517
2,631
2,466
10,340
2025
2,632
2,619
- -
2,627
10,550
2026
2,390
2,085
2,045
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.16
0.07
0.07
0.52
2025
0.17
0.09
- -
0.07
0.46
2026
0.31
0.24
0.44
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.03
0.13
2025
0.02
0.23
- -
0.02
0.29
2026
0.01
0.22
0.01
- -
- -
Business
Zhejiang Hisun Pharmaceutical Co., Ltd. Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) is a China-based pharmaceutical company engaged in the research, development, production, and sale of innovative drugs, biological drugs, generic drugs, and high-end active pharmaceutical ingredients (APIs). The company offers a broad portfolio of products covering more than ten therapeutic areas, including anti-tumor drugs, anti-infection drugs, cardiovascular drugs, endocrine drugs, immunosuppression drugs, antidepressants, liver care treatments, orthopedics drugs, antiparasitic drugs, veterinary drugs, anti-viral drugs, anti-TB drugs, weight loss drugs, and animal healthcare products; it manufactures both APIs and finished dosage forms such as capsules, tablets, and injectables. Zhejiang Hisun Pharmaceutical Co., Ltd. operates manufacturing facilities in locations including Taizhou, Fuyang, and Nantong, exports APIs to approximately 70 countries worldwide with 80% of API revenue from overseas markets, and maintains a domestic sales network covering all of China with products prescribed in nearly 10,000 hospitals; founded in 1956 and headquartered in Taizhou, Zhejiang Province, China, it employs over 5,000 people and ranks among China's largest producers of antibiotics and anti-tumor drugs. In recent developments, the company signed a Memorandum of Understanding in December 2024 with Sijilmasa Ltd. and One Belt and One Road Group Limited to build pharmaceutical plants in Morocco and the UAE, aiming to expand in the Middle East and Africa; it completed the acquisition of the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse, strengthening its control over key assets; and on November 10, 2025, announced plans to list a 100% stake in its wholly-owned subsidiary Provincial Pharmaceutical Company on the Taizhou Property Rights Exchange with a minimum price of RMB 4.3 billion. The company also received China veterinary drug approvals in November 2025 for nystatin ointment and toltrazuril products, and continues to invest in R&D with over 1,000 patents applied for and advanced facilities including a state-level technology center and post-doctoral research center.